Grufity logoGrufity logo

Agilent Technologies Inc Stock Research

A

136.82USD+2.79(+2.08%)Market Closed

Market Summary

USD136.82+2.79
Market Closed
2.08%

A Stock Price

A RSI Chart

A Valuation

Market Cap

40.4B

Price/Earnings (Trailing)

32.19

Price/Sales (Trailing)

5.89

EV/EBITDA

22.07

Price/Free Cashflow

39.53

A Price/Sales (Trailing)

A Profitability

EBT Margin

21.96%

Return on Equity

23.64%

Return on Assets

11.91%

Free Cashflow Yield

2.53%

A Fundamentals

A Revenue

Revenue (TTM)

6.8B

Revenue Y/Y

11.39%

Revenue Q/Q

7.63%

A Earnings

Earnings (TTM)

1.3B

Earnings Y/Y

-16.74%

Earnings Q/Q

11.85%

Price Action

52 Week Range

112.32159.59
(Low)(High)

Last 7 days

-4.9%

Last 30 days

-13.3%

Last 90 days

-11.2%

Trailing 12 Months

3.2%

A Financial Health

Current Ratio

2.03

Debt/Equity

0.52

Debt/Cashflow

0.48

A Investor Care

Dividend Yield

0.61%

Dividend/Share (TTM)

0.84

Buy Backs (1Y)

2.32%

Diluted EPS (TTM)

4.18

Peers (Alternatives to Agilent Tech)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.4B
6.8B
-13.31% 3.22%
32.19
5.89
8.37% 3.64%
35.5B
4.6B
5.65% -27.02%
-8.07
7.75
1.28% -677.95%
32.5B
3.9B
-7.42% 9.05%
37.3
8.3
5.43% 13.46%
18.2B
3.0B
-10.97% -4.88%
25.66
6.11
6.68% 2.15%
15.9B
3.3B
-11.65% -27.44%
27.98
4.81
-34.64% -39.65%
MID-CAP
SMALL-CAP
2.0B
128.3M
-11.70% -1.09%
-6.37
15.61
-1.69% -73.40%
1.2B
185.3M
-5.41% -23.53%
-6
6.49
20.06% 3.42%
450.3M
105.5M
-12.44% -50.56%
-4.66
4.27
-4.55% -67.63%
405.5M
127.3M
-23.43% -69.17%
-2.54
3.19
-12.28% -38.43%
341.8M
27.8M
-23.57% -31.43%
-2.58
12.29
54.62% -83.06%
271.1M
138.6M
-29.13% -76.08%
-8.07
1.96
32.30% -57.86%
135.5M
65.0M
-20.46% -63.49%
-1.2
2.08
-23.92% -73.73%
117.4M
113.3M
-15.92% -55.18%
-12.34
1.04
-4.68% -3204.17%
54.2M
54.1M
-0.24% -45.98%
502.17
1
21.80% -72.38%

Financials for Agilent Tech

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue2.8%6,8486,6596,5276,4456,319
  S&GA Expenses2.1%1,6371,6041,5951,6291,619
  R&D Expenses0.6%467464461455441
Costs and Expenses2.2%5,2305,1175,0605,0504,972
EBITDA-0.1%1,9051,9071,843--
EBITDA Margin-2.9%0.28*0.29*0.28*--
Earnings Before Taxes0.5%1,5041,4971,4271,3671,360
EBT Margin-2.3%0.22*0.22*0.22*--
Interest Expenses2.4%84.0082.0084.0083.0081.00
Net Income-5.6%1,2541,3281,2631,2051,210
Net Income Margin-8.2%0.18*0.20*0.19*--
Free Cahsflow-0.1%1,0211,0221,058--
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets0.5%10,53210,48410,45510,32710,705
  Current Assets2.4%3,7783,6903,6433,4743,799
    Cash Equivalents-1.7%1,0531,0711,1861,1131,484
  Inventory2.8%1,0381,010937879830
  Net PPE4.4%1,1001,0541,010974945
  Goodwill0.1%3,9523,9483,9563,9643,975
Liabilities-3.1%5,2275,3935,3335,1735,316
  Current Liabilities-2.2%1,8611,9021,8131,5841,708
.    Short Term Borrowings-80.0%36.00180175--
  Long Term Debt0.0%2,7332,7322,729--
    LT Debt, Non Current0%2,7302,7302,729--
Shareholder's Equity4.2%5,3055,0915,1225,1545,389
  Retained Earnings133.1%324139160159348
  Additional Paid-In Capital0.3%5,3255,3115,2925,2905,320
Shares Outstanding-0.3%295296299300302
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations0.5%1,3121,3051,3131,5021,485
  Share Based Compensation3.3%125121115114110
Cashflow From Investing-17.8%-338-287-275-786-749
Cashflow From Financing-1.3%-1,372-1,355-1,215-926-696
  Dividend Payments5.9%250236---
  Buy Backs-0.1%1,1391,140930891788

Risks for A

What is the probability of a big loss on A?

39.6%


Probability that Agilent Tech stock will be more than 20% underwater in next one year

11.5%


Probability that Agilent Tech stock will be more than 30% underwater in next one year.

0%


Probability that Agilent Tech stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does A drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Agilent Tech was unfortunately bought at previous high price.

Drawdowns

Returns for A

Cumulative Returns on A

16.7%


10-Year Cumulative Returns

20.2%


7-Year Cumulative Returns

14.7%


5-Year Cumulative Returns

25.4%


3-Year Cumulative Returns

What are the long-term rolling returns for A?

FIve years rolling returns for Agilent Tech.

Annualized Returns

Which funds bought or sold A recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-43.04
-184,861
434,139
0.01%
2023-03-10
MATHER GROUP, LLC.
added
9.38
359,680
1,399,680
0.03%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
22.85
70,395,200
207,743,000
0.23%
2023-03-06
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
unchanged
-
147,656
788,656
0.30%
2023-03-06
Rockefeller Capital Management L.P.
added
19.65
370,000
1,151,000
0.01%
2023-03-03
TIAA, FSB
added
0.8
128,256
660,256
-%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
866,473
866,473
0.01%
2023-02-28
CYPRESS ASSET MANAGEMENT INC/TX
unchanged
-
119,012
636,012
0.23%
2023-02-28
Voya Investment Management LLC
reduced
-10.5
10,070,500
108,935,000
0.15%
2023-02-27
CASCADE INVESTMENT GROUP, INC.
new
-
574,791
574,791
0.60%

1–10 of 46

Latest Funds Activity

Are funds buying A calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own A
No. of Funds

Agilent Tech News

Investor's Business Daily

Stocks Showing Improved Relative Strength: Agilent Technologies ....

Investor's Business Daily,
19 days ago

Investor's Business Daily

Investor's Business Daily

Investor's Business Daily

Investor's Business Daily

Investor's Business Daily

Investor's Business Daily

Medical Device Network

Leading medical companies in the robotics theme.

Medical Device Network,
3 months ago

Medical Device Network

Medical Device Network

Leading medical companies in the genomics theme.

Medical Device Network,
3 months ago

Investor's Business Daily

Investor's Business Daily

Recession Is Here Now, Says Red-Hot Investor.

Investor's Business Daily,
4 months ago

Investor's Business Daily

Schedule 13G FIlings of Agilent Tech

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
2.6%
7,707,066
SC 13G/A
Feb 09, 2023
vanguard group inc
8.53%
25,250,988
SC 13G/A
Jan 26, 2023
blackrock inc.
10.9%
32,309,878
SC 13G/A
Jan 20, 2023
blackrock inc.
10.9%
32,309,878
SC 13G/A
Apr 08, 2022
blackrock inc.
10.0%
30,082,335
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
7.1%
21,689,105
SC 13G/A
Feb 09, 2022
vanguard group inc
8.04%
24,269,735
SC 13G/A
Feb 03, 2022
blackrock inc.
9.7%
29,352,219
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
7.6%
23,512,823
SC 13G/A
Feb 10, 2021
vanguard group inc
7.76%
23,804,938
SC 13G/A

A Fair Value

Agilent Tech fair value in different scenarios

The table shows the Fair Value estimates for Agilent Tech for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

64.63

-52.76%

78.57

-42.57%

103.33

-24.48%

133.55

-2.39%

169.19

23.66%
Current Inflation

59.19

-56.74%

70.91

-48.17%

91.45

-33.16%

116.54

-14.82%

146.16

6.83%
Very High Inflation

52.53

-61.61%

61.73

-54.88%

77.55

-43.32%

96.94

-29.15%

119.90

-12.37%

Historical Agilent Tech Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Agilent Tech

View All Filings
Date Filed Form Type Document
Mar 16, 2023
4
Insider Trading
Mar 03, 2023
10-Q
Quarterly Report
Feb 28, 2023
8-K
Current Report
Feb 22, 2023
DEFA14A
DEFA14A
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 03, 2023
ARS
ARS
Feb 03, 2023
DEF 14A
DEF 14A
Jan 26, 2023
SC 13G/A
Major Ownership Report
Jan 20, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for A

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-12-14
Ancher-Jensen Henrik
sold
-4,595,510
155
-29,500
sr vice president
2022-12-13
MCDONNELL PADRAIG
sold
-107,520
160
-672
sr. vice president
2022-12-13
Grau Dominique
sold
-636,800
159
-4,000
senior vice president
2022-12-06
KOH BOON HWEE
sold
-1,978,690
152
-13,000
-
2022-12-01
Thaysen Jacob
sold
-503,528
155
-3,235
sr. vice president
2022-11-30
Thaysen Jacob
sold
-1,499,910
154
-9,700
sr. vice president
2022-11-23
Gonsalves Rodney
gifted
-143,543
155
-924
v.p., corporate controller
2022-11-23
Gonsalves Rodney
sold
-723,831
156
-4,634
v.p., corporate controller
2022-11-23
Gonsalves Rodney
gifted
143,543
155
924
v.p., corporate controller

1–10 of 50

Michael R. McMullen
17000
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

A Income Statement

2023-01-31
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Net revenue:  
Net revenue$ 1,756$ 1,674
Costs and expenses:  
Cost of revenue788764
Research and development123117
Selling, general and administrative419417
Total costs and expenses1,3301,298
Income from operations426376
Interest income91
Interest expense(25)(21)
Other income (expense), net0(37)
Income before taxes410319
Provision for income taxes5836
Net income$ 352$ 283
Net income per share  
Basic$ 1.19$ 0.94
Diluted$ 1.19$ 0.93
Weighted average shares used in computing net income per share:  
Basic296301
Diluted297303
Product  
Net revenue:  
Net revenue$ 1,323$ 1,263
Costs and expenses:  
Cost of revenue556545
Service and Other  
Net revenue:  
Net revenue433411
Costs and expenses:  
Cost of revenue$ 232$ 219

A Balance Sheet

2023-01-31
CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($)
$ in Millions
Jan. 31, 2023
Oct. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,250$ 1,053
Accounts receivable, net1,4591,405
Inventory1,1111,038
Other current assets258282
Total current assets4,0783,778
Property, plant and equipment, net1,1471,100
Goodwill3,9833,952
Other intangible assets, net810821
Long-term investments188195
Other assets713686
Total assets10,91910,532
Current liabilities:  
Accounts payable540580
Employee compensation and benefits296455
Deferred revenue521461
Short-term debt23836
Other accrued liabilities341329
Total current liabilities1,9361,861
Long-term debt2,7332,733
Retirement and post-retirement benefits9997
Other long-term liabilities542536
Total liabilities5,3105,227
Commitments and Contingencies (Note 9 and 12)
Stockholders' equity:  
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding00
Common stock; $0.01 par value; 2 billion shares authorized; 296 million shares at January 31, 2023 and 295 million shares at October 31, 2022, issued and outstanding33
Additional paid-in-capital5,3455,325
Retained earnings541324
Accumulated other comprehensive loss(280)(347)
Total stockholder's equity5,6095,305
Total liabilities and equity$ 10,919$ 10,532